| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Medicagenic acid targets fungal pathogens, exhibiting potent fungistatic effects. It has low inhibitory activity against xanthine oxidase, collagenase, elastase, tyrosinase, and ChE. The compound's mechanism involves antifungal activity, primarily targeting fungal cell membranes. Its anti-inflammatory and antioxidant effects suggest modulation of inflammatory pathways and oxidative stress.
|
|---|---|
| ln Vitro |
Medicagenic acid demonstrates potent in vitro fungistatic effects against several plant pathogens and human dermatophytes. It has low enzyme inhibitory activities against xanthine oxidase, collagenase, elastase, tyrosinase, and ChE. The compound exhibits anti-inflammatory, antimicrobial, and antioxidant effects. Its activity is typically assessed in antifungal susceptibility assays and enzyme inhibition assays.
|
| ln Vivo |
In vivo activity of medicagenic acid has been suggested by its anti-inflammatory, antimicrobial, and antioxidant effects. Studies suggest that medicagenic acid may help reduce inflammation and support immune health. Further in vivo studies are needed to evaluate its efficacy in models of fungal infection, inflammation, and oxidative stress.
|
| Enzyme Assay |
In vitro enzyme assays for medicagenic acid involve measuring its inhibition of xanthine oxidase, collagenase, elastase, tyrosinase, and ChE. The assays typically use purified enzymes and measure enzymatic activity in the presence of the compound. IC50 values can be determined from dose-response curves. Antifungal activity is assessed using standard fungal growth inhibition assays.
|
| Cell Assay |
In vitro cellular assays for medicagenic acid involve culturing fungal pathogens (e.g., dermatophytes, plant pathogens) in the presence of varying concentrations of the compound. Antifungal activity is assessed by measuring inhibition of growth using optical density measurements or colony counting. Anti-inflammatory activity can be evaluated by measuring cytokine production in activated immune cells.
|
| Animal Protocol |
In vivo animal experiments for medicagenic acid are not extensively documented. If used in animal models of fungal infection, inflammation, or oxidative stress, typical protocols would involve administering the compound to infected or stressed animals and evaluating efficacy by measuring pathogen load, inflammatory markers, or oxidative damage biomarkers.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for medicagenic acid are limited. As a triterpenoid pentacyclic glycoside, its absorption, distribution, metabolism, and excretion properties would influence its bioavailability. Further pharmacokinetic studies are needed to determine its systemic exposure and elimination pathways for potential therapeutic applications.
|
| Toxicity/Toxicokinetics |
Toxicological data for medicagenic acid are limited. As a natural product-derived compound, it is generally considered to have low toxicity, but comprehensive toxicological studies have not been reported. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Medicagenic acid is a triterpenoid compound. It has been reported to be found in alfalfa, granada alfalfa, and other organisms with relevant data.
Medicagenic acid (Castanogenin) (CAS#: 599-07-5) has the molecular formula C30H46O6 and a molecular weight of 502.68. It is a bioactive triterpenoid pentacyclic glycoside isolated from Herniaria glabra L. The compound exhibits potent fungistatic effects against several plant pathogens and human dermatophytes. It has low enzyme inhibitory activities against xanthine oxidase, collagenase, elastase, tyrosinase, and ChE. It is for research use only. |
| Molecular Formula |
C30H46O6
|
|---|---|
| Molecular Weight |
502.68
|
| Exact Mass |
502.329
|
| CAS # |
599-07-5
|
| PubChem CID |
65048
|
| Appearance |
White to off-white solid powder
|
| Density |
1.23g/cm3
|
| Boiling Point |
635.9ºC at 760 mmHg
|
| Melting Point |
380-382ºC (dec.)
|
| Flash Point |
352.4ºC
|
| Index of Refraction |
1.587
|
| LogP |
5.269
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
36
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@@H]([C@@H]([C@@]3(C)C(=O)O)O)O)C
|
| InChi Key |
IDGXIXSKISLYAC-WNTKNEGGSA-N
|
| InChi Code |
InChI=1S/C30H46O6/c1-25(2)11-13-30(24(35)36)14-12-27(4)17(18(30)15-25)7-8-20-26(3)16-19(31)22(32)29(6,23(33)34)21(26)9-10-28(20,27)5/h7,18-22,31-32H,8-16H2,1-6H3,(H,33,34)(H,35,36)/t18-,19-,20+,21+,22-,26+,27+,28+,29-,30-/m0/s1
|
| Chemical Name |
(2S,3R,4S,4aR,6aR,6bS,8aS,12aS,14aR,14bR)-2,3-dihydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (198.93 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (4.97 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.97 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.97 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9893 mL | 9.9467 mL | 19.8934 mL | |
| 5 mM | 0.3979 mL | 1.9893 mL | 3.9787 mL | |
| 10 mM | 0.1989 mL | 0.9947 mL | 1.9893 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
